Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- [Data] Sales of Daiichi Sankyo's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Eisai's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Mitsubishi Tanabe's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Dainippon Sumitomo's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Taisho HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Shionogi's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Ono's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Santen's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kyorin HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kaken's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Mochida's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Nippon Shinyaku's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kissei's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Zeria's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Fuso's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of ASKA's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Nippon Chemiphar's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Wakamoto's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Torii’s Mainstay Products in FY2011
June 19, 2012
- Merck of Germany Considers Entry into Japanese Biosimilars Market
June 18, 2012
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…